Recent studies have supported NRP1 as a potential tumor anti-angiogenesis therapeutic target, and NRP1-neutralizing antibodies or small-molecule antagonists have been shown to suppress tumor growth in an additive manner to VEGF neutralization (38). Here, NRP1 is linked to neoplasm.